Periodic Phlebotomy for Health & Longevity - Quick Reference Sheet

Periodic Phlebotomy for Health & Longevity

Created on 07/11/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Scheduled blood removal reliably lowers the body's iron. For adults carrying too much iron, modest, carefully tested draws appear low-risk and may improve metabolic and blood-pressure markers, though heart and longevity benefits remain unproven. For those with normal iron, the likely result is harmful iron shortage rather than gain. (Full Review)

Protocol

Volume per draw
450–500 mL
Standard whole-blood draw per session
Frequency
1–4×/year
Optimization schedule; blood donation 2–3×/year approximates this
Ferritin target
~25–75 ng/mL
Modest window, not maximal depletion
Time to effect
Iron stores
Immediate
Fall with each draw
Metabolic effects
Weeks–months
Insulin, blood pressure, liver markers in trials
Target ferritin
Several draws
Induction phase to reach a low target

Benefits

Contraindications
  • Hemoglobin below ~12.5 g/dL or ferritin below ~30 ng/mL
  • Iron-deficiency anemia
  • Pregnancy or breastfeeding
  • Unstable cardiovascular disease, recent myocardial infarction (within ~90 days), or significant aortic stenosis
  • Bleeding disorders
Key Interactions
  • Iron supplements and iron-fortified products
  • Vitamin C (ascorbic acid)
  • Erythropoiesis-stimulating agents (EPO) and testosterone
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, aspirin, clopidogrel)
  • Proton-pump inhibitors and antacids (omeprazole, calcium carbonate)
  • Additive iron-lowering interventions (frequent blood donation, chelation, low-heme diet, endurance exercise)

Risk & Side Effects

  • High: Iron deficiency and iron-deficiency anemia; vasovagal reactions
  • Medium: Fatigue and reduced physical performance; worsening or onset of restless legs syndrome
  • Low: Local venipuncture complications
  • Speculative: Impaired cognitive performance from iron depletion; rebound increase in dietary iron absorption

Monitoring

Marker Target Why
Ferritin ~30–75 ng/mL (avoid <30) Primary marker of body iron and the target of phlebotomy
Transferrin saturation (TSAT) ~20–45% Reflects circulating iron; high values flag overload
Hemoglobin / CBC ~13–15 g/dL (men), ~12–14 g/dL (women) Ensures draws are not causing anemia; safety gate
hs-CRP <1.0 mg/L Distinguishes true overload from inflammation-driven high ferritin
Fasting glucose & insulin (HOMA-IR) Glucose 70–90 mg/dL; HOMA-IR <1.5 Tracks the proposed metabolic benefit of iron reduction
Liver enzymes (ALT) <25 U/L (men), <20 U/L (women) Monitors the liver-related benefit in fatty liver disease
Blood pressure <120/80 mmHg Captures the possible vascular benefit seen in trials

Cadence: Ferritin and hemoglobin before each draw; fuller panel at baseline, ~3 months into an active phase, then every 6–12 months during maintenance

Qualitative Assessment

  • Energy and exercise tolerance
  • Restless legs or nighttime leg discomfort
  • Cognitive clarity and mood
  • Recovery after each draw